The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris.
Marie-Claude Morice, Antonio Colombo, Bernhard Meier, Patrick W. Serruys, Corrado Tamburino, Giulio Guagliumi, Eduardo Sousa, Hans-Peter Stoll, for the REALITY Trial Investigators
Evelyn Regar, Patrick W. Serruys, C Bode, C Holubarsch, J L Guermonprez, William Wijns, Antonio L. Bartorelli, Constantino Constantini, Muzaffer Değertekin, Kengo Tanabe, Clemens Disco, Egon Wuelfert, Marie-Claude Morice
Angela Hoye, Pedro A. Lemos, Chourmouzios A. Arampatzis, Francesco Saia, Kengo Tanabe, Muzaffer Değertekin, Joost Daemen, Pieter C. Smits, Eugène McFadden, Sjoerd H. Hofma, Georgios Sianos, Pim de Feyter, Willem J. van der Giessen, Ron T. van Domburg, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.